相似文献
1
Systemic therapy for advanced pancreatic neuroendocrine tumors.
Semin Oncol. 2013 Feb;40(1):75-83. doi: 10.1053/j.seminoncol.2012.11.010.
2
Sunitinib and everolimus in pancreatic neuroendocrine tumors.
Tumori. 2012 May-Jun;98(3):394. doi: 10.1177/030089161209800319.
3
Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Anticancer Agents Med Chem. 2013 Mar;13(3):382-8.
4
Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.
J Clin Oncol. 2015 May 10;33(14):1534-8. doi: 10.1200/JCO.2014.59.0927. Epub 2015 Apr 13.
5
Neuroendocrine tumors: treatment updates.
JOP. 2013 Jul 10;14(4):367-71. doi: 10.6092/1590-8577/1657.
6
Novel agents in gastroenteropancreatic neuroendocrine tumors.
JOP. 2013 Mar 10;14(2):152-4. doi: 10.6092/1590-8577/1470.
7
Pancreatic neuroendocrine neoplasms.
Minerva Gastroenterol Dietol. 2012 Dec;58(4):401-26.
8
New targeted agents in gastroenteropancreatic neuroendocrine tumors.
Target Oncol. 2012 Jun;7(2):99-106. doi: 10.1007/s11523-012-0218-9. Epub 2012 May 15.
9
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S87-94. doi: 10.1016/S0305-7372(10)70026-8.
10
[Drug therapy for neuroendocrine tumours].
Orv Hetil. 2013 Sep 29;154(39):1556-64. doi: 10.1556/OH.2013.29718.
引用本文的文献
1
Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.
Int J Surg Oncol. 2017;2017:6424812. doi: 10.1155/2017/6424812. Epub 2017 May 16.
2
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Pancreas. 2015 Mar;44(2):181-9. doi: 10.1097/MPA.0000000000000262.
3
Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths.
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1825-30. doi: 10.1007/s00259-014-2780-0.
4
Zollinger-Ellison syndrome: recent advances and controversies.
Curr Opin Gastroenterol. 2013 Nov;29(6):650-61. doi: 10.1097/MOG.0b013e328365efb1.
5
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.
Nat Rev Drug Discov. 2013 Oct;12(10):743-55. doi: 10.1038/nrd4101. Epub 2013 Sep 6.
本文引用的文献
1
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.
J Clin Oncol. 2012 Apr 1;30(10):1100-6. doi: 10.1200/JCO.2011.37.2151. Epub 2012 Mar 5.
2
Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
J Nucl Med. 2011 Sep;52(9):1361-8. doi: 10.2967/jnumed.111.087932. Epub 2011 Jul 27.
3
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
J Clin Oncol. 2011 Jun 10;29(17):2416-23. doi: 10.1200/JCO.2010.33.7873. Epub 2011 May 9.
4
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Endocrinol Metab Clin North Am. 2011 Mar;40(1):173-85, ix. doi: 10.1016/j.ecl.2010.12.003.
5
New and emerging syndromes due to neuroendocrine tumors.
Endocrinol Metab Clin North Am. 2011 Mar;40(1):19-63, vii. doi: 10.1016/j.ecl.2010.12.010.
6
Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors.
Cancer Metastasis Rev. 2011 Mar;30 Suppl 1:27-34. doi: 10.1007/s10555-011-9290-3.
7
Everolimus for advanced pancreatic neuroendocrine tumors.
N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.
8
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825.
9
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Science. 2011 Mar 4;331(6021):1199-203. doi: 10.1126/science.1200609. Epub 2011 Jan 20.
10
mTOR: from growth signal integration to cancer, diabetes and ageing.
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15.
Zotero 插件